3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Colorectal Neoplasms
2
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Papillomavirus Infections
1
Neoplasms
1
Neoplasm, Residual
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Hairy Cell
1
Hemorrhage
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Carboplatin
15
durvalumab
14
Etoposide
14
pembrolizumab
9
atezolizumab
9
Cisplatin
9
Topotecan
8
Nivolumab
7
Specimen Handling
6
olaparib
4
berzosertib
4
Temozolomide
4
Magnetic Resonance Spectroscopy
4
AMG 757
4
tremelimumab
3
Radiotherapy
3
Radiosurgery
3
PM 01183
3
Ipilimumab
3
Docetaxel
3
Biopsy
3
niraparib
2
lenvatinib
2
cabozantinib
2
Platinum
2
Irinotecan
2
Fulvestrant
2
veliparib
1
tislelizumab
1
tazemetostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Small Cell Lung Carcinoma
×
Sodium Chloride
×
Clear all
NCT04624204
2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
672 enrolled